| Engineering strategies to overcome the current roadblocks in CAR T cell therapy S Rafiq, CS Hackett, RJ Brentjens Nature Reviews Clinical Oncology, 1-21, 2019 | 1124 | 2019 |
| Driving CAR T-cells forward HJ Jackson, S Rafiq, RJ Brentjens Nature reviews Clinical oncology 13 (6), 370-383, 2016 | 719 | 2016 |
| Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo S Rafiq, OO Yeku, HJ Jackson, TJ Purdon, DG van Leeuwen, DJ Drakes, ... Nature biotechnology 36 (9), 847-856, 2018 | 683 | 2018 |
| Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity HE Kohrt, I Sagiv-Barfi, S Rafiq, SEM Herman, JP Butchar, C Cheney, ... Blood, The Journal of the American Society of Hematology 123 (12), 1957-1960, 2014 | 238 | 2014 |
| Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals R Lapalombella, YY Yeh, L Wang, A Ramanunni, S Rafiq, S Jha, J Staubli, ... Cancer cell 21 (5), 694-708, 2012 | 172 | 2012 |
| Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma VV Leshchenko, PY Kuo, R Shaknovich, DT Yang, T Gellen, A Petrich, ... Blood, The Journal of the American Society of Hematology 116 (7), 1025-1034, 2010 | 168 | 2010 |
| Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen S Rafiq, TJ Purdon, AF Daniyan, M Koneru, T Dao, C Liu, DA Scheinberg, ... Leukemia 31 (8), 1788-1797, 2017 | 158 | 2017 |
| Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties S Rafiq, JP Butchar, C Cheney, X Mo, R Trotta, M Caligiuri, D Jarjoura, ... The Journal of Immunology 190 (6), 2702-2711, 2013 | 126 | 2013 |
| Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages M Song, OO Yeku, S Rafiq, T Purdon, X Dong, L Zhu, T Zhang, H Wang, ... Nature communications 11 (1), 6298, 2020 | 100 | 2020 |
| Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia CH Jin, J Xia, S Rafiq, X Huang, Z Hu, X Zhou, RJ Brentjens, YG Yang EBioMedicine 39, 173-181, 2019 | 60 | 2019 |
| CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? HJ Pegram, EL Smith, S Rafiq, RJ Brentjens Immunotherapy 7 (5), 545-561, 2015 | 45 | 2015 |
| Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia CM Cheney, DM Stephens, X Mo, S Rafiq, J Butchar, JM Flynn, JA Jones, ... MAbs 6 (3), 748-754, 2014 | 45 | 2014 |
| Tumors evading CARs—the chase is on S Rafiq, RJ Brentjens Nature medicine 24 (10), 1492-1493, 2018 | 44 | 2018 |
| Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity H Fan, S Xia, J Xiang, Y Li, MO Ross, SA Lim, F Yang, J Tu, L Xie, ... Nature 623 (7989), 1034-1043, 2023 | 31 | 2023 |
| Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma PR Baum, C Cerveny, B Gordon, C Nilsson, J Wiens, S Rafiq, ... Journal of Clinical Oncology 27 (15_suppl), 8571-8571, 2009 | 30 | 2009 |
| Optimization of T-cell receptor–modified T cells for cancer therapy DJ Drakes, S Rafiq, TJ Purdon, AV Lopez, SS Chandran, CA Klebanoff, ... Cancer immunology research 8 (6), 743-755, 2020 | 24 | 2020 |
| Excessive costimulation leads to dysfunction of adoptively transferred T cells D Wijewarnasuriya, C Bebernitz, AV Lopez, S Rafiq, RJ Brentjens Cancer immunology research 8 (6), 732-742, 2020 | 23 | 2020 |
| Engineered cytokines for cancer and autoimmune disease immunotherapy B Uricoli, LA Birnbaum, P Do, JM Kelvin, J Jain, E Costanza, A Chyong, ... Advanced healthcare materials 10 (15), 2002214, 2021 | 22 | 2021 |
| Inhibition of human erythrocyte invasion by Babesia divergens using serine protease inhibitors. E Montero, S Rafiq, S Heck, CA Lobo | 20 | 2007 |
| A phase 1 trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIPTM) protein in relapsed and refractory CLL: early promising clinical activity. L Andritsos, RR Furman, IW Flinn, A Foreno-Torres, JM Flynn, ... Blood 114 (22), 3424, 2009 | 18 | 2009 |